STUDY. Treatment of Undifferentiated Vulvar Intraepithelial Neoplasia With 5% Imiquimod Cream
|
|
- Megan Cobb
- 5 years ago
- Views:
Transcription
1 Treatment of Undifferentiated Vulvar Intraepithelial Neoplasia With 5% Imiquimod Cream A Prospective Study of 12 Cases STUDY Jeanne Wendling, MD; Philippe Saiag, MD, PhD; Sophie Berville-Levy, MD; Isabelle Bourgault-Villada, MD, PhD; Thierry Clerici, MD; Micheline Moyal-Barracco, MD Objective: To assess the efficacy of 5% imiquimod cream on undifferentiated vulvar intraepithelial neoplasia (VIN), a disease caused by high-risk human papillomavirus. Design: Prospective, uncontrolled study. Setting: University hospital vulvar clinic. Patients: Twelve consecutive patients treated with 5% imiquimod cream for undifferentiated VIN between March 1, 1999, and May 31, Intervention: Self-application of 5% imiquimod cream, initially 3 times a week, then adjusted according to tolerance, for up to 7 months according to clinical response. Main Outcome Measures: Therapeutic response, clinically assessed by successive photographs and histologically confirmed for complete responders, was scored as complete, partial ( 50% decrease in lesion size), or failure. Tolerance was evaluated at each visit. Results: A total of 3, 4, and 5 patients achieved complete response, partial response ( 75% reduction in lesion size for all such cases), and failure, respectively. Mean duration of treatment was 3.6 months (37.3 applications), 5.0 months (50.7 applications), and 3.4 months (25.2 applications) for complete responders, partial responders, and failures, respectively. Follow-up after treatment was 5 to 18, 14 to 32, and 2 to 28 months, respectively, with 1 partial responder lost to long-term followup. No patient developed invasive carcinoma. All but 2 patients experienced vulvar discomfort, resulting in treatment withdrawal for 3. Two patients had flulike symptoms. Conclusions: Imiquimod cream could be a therapeutic option for undifferentiated VIN. Although poorly tolerated, this self-applied treatment could spare patients, either totally or partially, the classic painful and sometimes mutilating treatments of VIN. Controlled, randomized studies are needed to evaluate its efficacy and tolerance. Arch Dermatol. 2004;140: From the Service de Dermatologie Générale et Oncologique (Drs Wendling, Saiag, Berville-Levy, Bourgault-Villada, and Moyal-Barracco) and Service d Anatomopathologie (Dr Clerici), Hôpital Ambroise-Paré, Assistance Publique des Hôpitaux de Paris, Université Versailles Saint-Quentin en Yvelines, Boulogne, France. The authors have no relevant financial interest in this article. VULVAR INTRAEPITHELIAL neoplasia (VIN) is an uncommon condition, but its annual incidence (approximately 1.8 new cases per women) has increased during the past 2 decades. 1 Vulvar intraepithelial neoplasia, also described as highgrade VIN or VIN 2-3, is divided into 2 categories 2 : undifferentiated VIN, which is defined by full-thickness cytologic and architectural epithelial atypias, and differentiated VIN, which is characterized by cytologic and architectural atypias confined to the basal layers of the epithelium. Differentiated VIN mainly affects postmenopausal women, does not usually contain human papillomavirus (HPV) DNA sequences, and is frequently associated with an inflammatory condition (lichen sclerosus or lichen planus). A strong link has been documented between differentiated VIN and HPV-negative vulvar carcinoma. 2 In one series, 3 58% of the patients with differentiated VIN had prior or synchronous, invasive, keratinizing, vulvar squamous cell carcinoma (SCC) or developed it subsequently. In contrast to differentiated VIN, undifferentiated VIN predominantly affects women in their 30s and 40s and is associated with high-risk HPV types, mainly HPV-16. It has also been termed vulvar carcinoma in situ, vulvar atypia, bowenoid papulosis, Bowen disease, and erythroplasia of Queyrat. The last 2 entities usually designate monofocal lesions that occur in patients older than 50 years as opposed to the most frequently encountered bowenoid papulosis, which applies to multifocal pseudocondylomatous lesions that occur in younger patients. Only 3% to 10% of the patients treated for undifferentiated VIN subsequently develop invasive SCC of the 1220
2 vulva. 2 Current treatments for undifferentiated VIN consist of physical destruction of the lesions by partial vulvectomy, cryotherapy, laser vaporization, or electrocoagulation. These painful, sometimes mutilating, treatments do not protect the patients from recurrences, which occur in 12% to 58% of women after treatment. 4-6 Imiquimod, an imidazoquinoline amine, is an immune-response modifier that induces monocytes and macrophages to produce interferon- and other cytokines (interleukins 1, 6, 8, 10, and 12 and tumor necrosis factor ). It inhibits viral replication and promotes stronger cellmediated immune responses. 7 Self-administered 5% imiquimod cream (Aldara; Laboratoire 3M Santé, Division 3M Pharma, Cergy-Pontoise, France) is currently approved for treating anogenital warts (AGWs), a condition related to low-risk HPV infection, with complete responses achieved in 35% to 52% of immunocompetent patients. 8,9 In addition, phase 2 studies have shown that 5% imiquimod cream can be an effective treatment of superficial basal cell carcinoma, actinic keratoses, and extragenital Bowen disease. 10,11 We postulated that 5% imiquimod cream could represent a conservative alternative to the current destructive treatments of undifferentiated VIN, both because this condition is HPV related and because it carries a low risk of invasive SCC. Therefore, it was acceptable to postpone the classic destructive treatment of the lesions until after failure or partial response to 5% imiquimod cream. METHODS From March 1, 1999, to May 31, 2001, 5% imiquimod cream was prospectively prescribed to all patients with histologically confirmed, noninvasive, undifferentiated VIN who consulted the vulvar clinic of our university hospital. During that period, 3 other patients with thick, monofocal, erythroplastic lesions were treated surgically, because we were not sure that the focal biopsy findings excluded SCC. The study followed the principles outlined in the Declaration of Helsinki. All patients gave informed oral consent. The initial evaluation consisted of an inspection of the vulva and the anal margin, first with the naked eye and then with a magnifying lens (original magnification 2), followed by a detailed, written description of the lesions, photographs, and drawn diagrams. Because of its lack of sensitivity and specificity, the acetic acid test was not used. Biopsy specimens were obtained from all ulcerated, leukoplastic, thick, and infiltrated areas before treatment to exclude invasive SCC. All patients who had not had a Papanicolaou smear during the preceding year were advised to have one performed by their gynecologist. Patients with lesions of the anal margin underwent anoscopy. The diagnosis of undifferentiated VIN was made based on histologic examination of the biopsy specimens by an experienced pathologist (T.C.). The women were offered HPV typing by polymerase chain reaction performed on a biopsy specimen of a representative lesion. Patients were instructed to apply 5% imiquimod cream (each dose of 12.5 mg supplied in individual packets) 3 times a week overnight, as recommended for the treatment of external genital warts. The areas involved by the VIN were shown to the patient using a mirror. She was then instructed to apply the cream on these specific areas with the fingers. When the lesions involved more than 50% of the surface of the vulvar mucosa, the patient was told to apply 1 complete packet of cream. In case of less extended lesions, she was instructed to apply a small quantity of cream. In these latter patients, we did not quantify the amount of cream applied. The cream was applied at bedtime and was removed by washing with water and a gentle soap in the morning. The patient was asked neither to wash nor to have sexual intercourse during the time the cream was in contact with the mucosa. The frequency of the applications was adapted as a function of the tolerance to the cream. Follow-up evaluations consisted of physical examination of the vulva, with detailed description of the lesions, photographs, and drawn diagrams made by 2 experienced physicians (M.M.-B., S.B.-L.). The number of applications, the duration of treatment, and tolerance of the cream were also recorded. Responses were evaluated clinically monthly, and 2 authors (J.W., M.M.-B.) reviewed successive photographs after completion of the study. A complete response was defined as histologically confirmed complete disappearance of the lesions. Partial response was defined as decrease of 50% or more in the lesion size, whereas a decrease of less than 50% of lesion size or progression was considered a failure. At the end of treatment, patients returned to usual follow-up and treatments by the same physicians. RESULTS Twelve consecutive patients fulfilled our criteria for inclusion (Table 1). Their ages ranged from 27 to 53 years (mean age, 41.4 years). Patients 6, 7, and 8 tested positive for human immunodeficiency virus (HIV) 1 and were undergoing highly active antiretroviral therapy (HAART) for more than 1 year with satisfactory responses (CD4 lymphocyte count of 350/µL, no detectable HIV-1 RNA in the serum for 2 of these patients, and 9000 copies/ml of plasma for the third). The VIN was recurrent in 8 patients. Four patients had histories of cervical intraepithelial neoplasias, and 1 had previously undergone surgery for anal intraepithelial neoplasia. All 12 patients had normal Papanicolaou smear results within the year preceding the 5% imquimod cream treatment. Seven of 12 patients had multifocal lesions, which involved more than 50% of the vulvar mucosa in 3 of them. In 5 women, the lesions were monofocal. Lesions were predominantly pink papules or macules. Patient 6 had a typical bowenoid papulosis. Ten patients underwent an additional biopsy for HPV testing: HPV-16 was found in 9 patients and HPV-33 in 1. Five percent imiquimod cream led to 3 complete responses, 4 partial responses, and 5 failures. None of the lesions progressed to invasive SCC. Patients 1, 2, and 3, who experienced biopsy-confirmed complete response and were not immunocompromised, initially had limited macular or papular pink lesions that involved less than 20% of the vulvar mucosa surface. Patients 2 and 3 had recurrent VIN. Imiquimod had been applied for a mean duration of 3.7 months (mean number of applications, 37.3). The HPV was no longer detected in a new biopsy specimen at the site of the pretreatment lesions in patient 1. Persistent HPV infection was not sought in the 2 other complete responders. No recurrence was observed during a mean follow-up of 9.7 months after the end of the treatment. Patients 4 to 7 experienced partial response, with regression of more than 75% of the lesion area in all of them. Their lesions at inclusion were polymorphous: macular, papular, or warty; pink or pigmented; multifo- 1221
3 Table 1. Main Characteristics of the 12 VIN Patients Patient No./ Age, y/ HIV Status Clinical Features of the Lesions Location of VIN (% of the Vulvar Mucosa Involved) Recurrent VIN Months Undergoing Treatment Applications Follow-up After Treatment, mo Response 1/51/ Pink; macular Multifocal ( 20); fourchette, No 4 28 Complete 18 posterior vestibule, anal margin 2/44/ Pink; papular or verrucous Multifocal ( 20); labia minora Yes 3 36 Complete 6 3/53/ Pink; macular Monofocal ( 20); fourchette Yes 4 48 Complete 5 4/27/ Pink or pigmented; papular Monofocal ( 20); left labium No 6 41 Partial 14 minus, posterior vestibule, fourchette 5/40/ Pink; papular or verrucous Monofocal (20-50); left labium minus 6/39/+ Pigmented; papular Multifocal ( 20); labia majora, fourchette, right labium minus, perineum, anal margin 7/40/+ Pink; macular or papular Multifocal (20-50); clitoris, labia majora and minora, perineum anal margin 8/40/+ Pink, white, or pigmented; Multifocal ( 50); labia majora papular, macular, or verrucous and minora, perineum anal margin 9/32/ Pink or pigmented; macular or papular Multifocal ( 50); labia majora and minora, perineum, anal margin Yes 7 78 Partial LFU No 6 72 Partial 15 Yes 1 12 Partial 32 Yes 3 24 Failure 13 Yes 3 36 Failure 28 10/47/ Pink; verrucous Monofocal ( 20); right labia No 3 36 Failure 2 Then LFU minora and majora, fourchette 11/40/ Pink or white; verrucous Multifocal ( 50); labia minora Yes 5 12 Failure 14 and majora, anal margin 12/44/ Pink, white, or pigmented; papular Monofocal (30); left labium minus Yes 3 18 Failure 11 Abbreviations: HIV, human immunodeficiency virus; LFU, lost to follow-up; VIN, vulvar intraepithelial neoplasia. cal or monofocal; and widespread or limited. Patients 5 and 7 had recurrent VIN, and patients 6 and 7 were HIV positive. Imiquimod had been applied for 1 to 7 months (mean duration, 5.0 months; mean number of applications, 50.7). Patient 5 was lost to follow-up after the end of the treatment. For the 3 others, mean follow-up was 20.3 months. Patient 4 underwent laser vaporization at the end of treatment, and the 2 others did not experience progression during follow-up. The remaining 5 women experienced treatment failure. Three of them had recurrent widespread lesions that involved more than 50% of the vulvar mucosa. Patient 8 was HIV positive, with a CD4 T-lymphocyte count of 600/ µl. These 5 women in whom the treatment failed had applied imiquimod for a mean duration of 3.4 months, with a low mean number of applications (25.2) because of either premature withdrawal for inefficacy or intolerance. Patient 10, whose lesions involved less than 20% of the vulvar mucosa, underwent excision of the remaining lesions but was lost to follow-up 2 months later. The mean duration of follow-up was 16.5 months for the remaining patients. No progression to invasive SCC was observed. Ten of the 12 patients experienced local adverse effects: itching (6/12), burning (8/12), or vulvar erosions (7/12). Patients 7, 8, and 12 stopped using imiquimod because of the local adverse effects. Patients 1 and 11 experienced flulike symptoms (fever, myalgia, and chills) similar to those observed with subcutaneous interferon. These symptoms appeared 8 to 12 hours after every topical application and disappeared within 1 hour with paracetamol or within 16 hours without any treatment. Patient 1 had a monofocal VIN that involved less than 20% of the vulvar mucosa, and patient 11 had an extensive VIN that involved almost the entire surface of the vulvar mucosa; both had superficial topical ulcers. The flulike symptoms decreased after 5 or 6 applications. Patient 8, who was HIV positive, developed cytolytic hepatitis during the treatment. This hepatitis relapsed after the end of the imiquimod treatment and was eventually attributed to HAART. COMMENT Seven of 12 patients with undifferentiated VIN treated with 5% imiquimod cream experienced either complete remission or partial remission. In the patients who experienced partial remission (initially defined as a reduction of 50% in lesion size), the decrease in lesion size was at least 75%. Imiquimod could be a valid alternative to the classic destructive treatment methods, because it can be self-applied by the patients and, theoretically, because it represents an immunologic approach to the management of this HPVassociated condition. Indeed, conventional treatments of undifferentiated VIN are painful and sometimes mutilating, and recurrences frequently occur. 5 Considering the low risk of transformation of undifferentiated VIN into SCC, the cost of conventional treatments most frequently exceeds their benefit. 1222
4 Table 2. Imiquimod for Treatment of VIN: Review of the Literature Responses Recurrences After Complete Response Source Study Type Patients Complete Partial (Regression 50% of the Lesion[s]) Failure and LFU van Seters et al, Prospective, uncontrolled NS NS Jayne and Kaufman, 17 Retrospective * 1 NS Todd et al, Prospective, uncontrolled (at 5 mo) 5 Petrow et al, Case report 1 1 None 18 Diaz-Arrastia et al, 14 Retrospective (at 15 mo) Davis et al, Case reports (at 12 mo) 12 Abbreviations: LFU, lost to follow-up; NS, not specified; VIN, vulvar intraepithelial neoplasia. *In this study, partial response was defined as at least 75% regression of the lesions. Mean Follow-up After Treatment, mo Our study included only 12 patients and was uncontrolled. However, it was prospective and used strict criteria to evaluate response to treatment. This study provides additional information about the efficacy and tolerance of imiquimod in undifferentiated VIN. Only 1 of 7 patients (patient 6) who responded to treatment, either completely or partially, had multifocal, pigmented, papular lesions, a clinical form of VIN for which spontaneous regression has been reported. 12 Therefore, we favor the hypothesis that our patients good outcomes were more likely due to the treatment than to spontaneous regression of the lesions. So far, to our knowledge, 6 studies concerning the treatment of VIN with self-applied 5% imiquimod cream have been published (Table 2) These studies, either case reports or uncontrolled trials, included in total 52 patients. Twenty-two (42%) of them achieved complete remission, 15 (29%) achieved partial remission, and 15 (29%) were deemed treatment failures or were lost to follow-up. Our findings are in agreement with those results, although no definitive conclusion can yet be drawn, because all these studies are uncontrolled and each includes no more than 15 patients. It is worth noting that, as opposed to our study, none of the previously published studies specified whether the VIN treated with imiquimod were differentiated or undifferentiated. Indeed, patients with differentiated VIN could have been included in those studies and that form of VIN could respond to imiquimod in a different way. The response in the 3 HIV-positive patients (all 3 undergoing HAART and with a CD4 T-lymphocyte count of 350/µL) did not seem different from that obtained in the HIV-negative population, although the number is too small to draw a definitive conclusion. Involvement of less than 50% of the vulvar mucosa might be predictive of a good response to imiquimod treatment. Indeed, our 7 patients who responded to this treatment had lesions that involved less than 50% of the vulvar mucosa, whereas therapy failed for our 3 patients with lesions that involved larger areas. In contrast, Diaz- Arrastia et al 14 reported that their 2 patients with extensive VIN achieved complete remission. However, the authors did not fully define the term extensive. Todd et al, 16 Jayne and Kaufman, 17 and van Seters et al 18 also did not specify the extent of the lesions in their patients. In future studies, response to treatment should be assessed according to the vulvar area initially involved. However, it remains difficult to measure the area of multifocal lesions, and a feasible and reproducible method still needs to be validated. In our study, VINs that responded to the treatment were almost equally distributed between monofocal and multifocal lesions and among papular, macular, and verrucous forms. In the absence of a validated clinical classification of VIN, an analysis of the response to imiquimod according to the morphologic features of the lesions would not be reliable. The VIN recurrence rates following partial vulvectomy or carbon dioxide laser vaporization ranged from 12% to 58%. 4-6 None of our 3 patients who obtained complete remission experienced a recurrence of the disease (follow-up range, 5-18 months). In the published studies on imiquimod-treated VIN, follow-up for recurrence after complete remission was performed in only 10 of 52 patients (Table 2) Additional studies are needed to determine if, compared with other treatments, imiquimod reduces the recurrence rate of undifferentiated VIN as observed in the treatment of AGWs. Indeed, according to the literature, recurrence rates of AGWs treated with 5% imiquimod vary from 13% to 19%, 19,20 whereas recurrence rates of those treated with podophyllin vary from 30% to 70% and from 58% to 70% with topical fluorouracil. 21 Local tolerance was poor in our study, as in the published reports, with burning, itching, and/or ulcers described. Patients frequently either stopped treatment or applied the cream less often. These results are in agreement with those of Todd et al, 16 who reported that 11 of the 13 patients whom they followed up (2 patients were lost to follow-up) developed local adverse effects. In the other published studies, topical intolerance was frequently reported but rarely led to treatment withdrawal. Local intolerance is a well-known adverse effect of treating AGWs with 5% imiquimod cream. In published controlled trials, erosions occurred in 10% to 58% of the patients, 19,20 and treatment withdrawal because of adverse effects ranged from 1% to 5%. 8 Additional studies should determine whether imiquimod is more irritating in the treatment of VIN than in the treatment of AGWs. Indeed, the tolerance of imiquimod could be related to the type of condition treated. Although there are 1223
5 no controlled studies about this subject, to our knowledge, it seems that topical irritation is more frequently observed in imiquimod-treated actinic keratosis (16% to 53% of severe reactions requiring a rest period) 22 and basal cell carcinomas (13% of severe local reactions leading to treatment withdrawal) 23 than in imiquimod-treated genital warts. Because of the high rate of local irritation in this study, we now start treatment at a lower frequency (once a week) and then adapt the regimen to local tolerance. Another way to improve local tolerance could be to shorten the duration of each application ( 6 hours) and reduce the quantity of cream applied. Flulike symptoms, similar to those reported during interferon therapy, occurred in 2 of our patients and had previously been observed in a phase 1 clinical trial of oral imiquimod in patients with refractory cancer. 24 As far as topical treatment is concerned, flulike symptoms did not occur with a significant frequency in the controlled trials concerning AGWs. 9 Among the studies concerning VIN treatment with imiquimod, only Todd et al 16 mentioned flulike symptoms in 2 of the 13 patients whom they followed up. These symptoms could result from imiquimod-induced cytokine release by responding cells within the lesion 25 and/or in the bloodstream. This flulike syndrome did not seem to be associated with the extent of the lesion or the presence of particularly severe ulcerations. In conclusion, 5% imiquimod cream was completely or more than 75% effective in 7 of 12 patients with undifferentiated VIN. These results, which are in agreement with most of the published data, support the hypothesis that imiquimod could be a therapeutic option for VIN, provided that previous biopsy specimens excluded the presence of SCC. However, additional controlled studies are needed to evaluate the efficacy of this treatment, to identify factors predictive of therapeutic response, and to decide whether imiquimod could be prescribed as conservative first-line treatment for undifferentiated VIN. Accepted for publication May 17, This study was presented in part at the Journées Dermatologiques de Paris; December 6, 2001; Paris, France. We thank Janet Jacobson, BS, and Luis Perez, PhD, for editing our English; Eric Julian, PhD, for the HPV typing; and Bernard-Jean Paniel, MD, for providing surgical or laser treatment to the patients in whom imiquimod treatment failed. Correspondence: Micheline Moyal-Barracco, MD, Service de Dermatologie Générale et Oncologique, Hôpital Ambroise-Paré, 9 Avenue Charles-de-Gaulle, Boulogne CEDEX, France (micheline.moyal-barracco@apr.ap-hop-paris.fr). REFERENCES 1. Joura EA. Epidemiology, diagnosis and treatment of vulvar intraepithelial neoplasia. Curr Opin Obstet Gynecol. 2002;14: Hart WR. Vulvar intraepithelial neoplasia: historical aspects and current status. Int J Gynecol Pathol. 2001;20: Yang B, Hart WR. Vulvar intraepithelial neoplasia of the simplex (differentiated) type: a clinicopathologic study including analysis of HPV and p53 expression. Am J Surg Pathol. 2000;24: Fiorica JV, Cavanagh D, Marsen DE, et al. Carcinoma in situ of the vulva: 24 years experience in Southwest Florida. Southern Med J. 1988;81: Kaufman RH. Intraepithelial neoplasia of the vulva. Gynecol Oncol. 1995;56: Herod JJO, Shafi MI, Rollasson TP, Jordan JA, Luesley DM. Vulvar intraepithelial neoplasia: long term follow-up of treated and untreated women. Br J Obstet Gynaecol. 1996;103: Dahl MV. Imiquimod: an immune response modifier. J Am Acad Dermatol. 2000; 43:S1-S5. 8. Moore RA, Edwards JE, Hopwood J, Hicks D. Imiquimod for the treatment of genital warts: a quantitative systematic review. BMC Infect Dis. 2001;1:3. 9. Perry CM, Lamb HM. Topical imiquimod: a review of its use in genital warts. Drugs. 1999;58: Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier 5% imiquimod cream. J Am Acad Dermatol. 1999;41: Mackenzie-Wood A, de Kossard S, Launey J, Wilkinson B, Owens ML. 5% imiquimod cream in the treatment of Bowen s disease. J Am Acad Dermatol. 2001; 44: Jones RW, Rowan DM. Spontaneous regression of vulvar intraepithelial neoplasia 2-3. Obstet Gynecol. 2000;96: Davis G, Wentworth J, Richard J. Self-administered topical imiquimod treatment of vulvar intraepithelial neoplasia: a report of four cases. J Reprod Med. 2000;45: Diaz-Arrastia C, Arany I, Robazetti SC, et al. Clinical and molecular responses in high-grade intraepithelial neoplasia treated with topical 5% imiquimod. Clin Cancer Res. 2001;7: Petrow W, Gerdsen R, Uerlich M, Richter O, Bieber T. Successful topical immunotherapy of bowenoid papulosis with imiquimod. Br J Dermatol. 2001;145: Todd RW, Etherington IJ, Luesley DM. The effects of 5% imiquimod cream on high-grade vulval intraepithelial neoplasia. Gynecol Oncol. 2002;85: Jayne CJ, Kaufman RH. Treatment of vulvar intraepithelial neoplasia 2/3 with imiquimod. J Reprod Med. 2002;47: van Seters M, Fons G, van Beurden M. Imiquimod in the treatment of multifocal vulvar intraepithelial neoplasia 2/3: results of a pilot study. J Reprod Med. 2002; 47: Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol. 1998;134: Beutner KR, Spruance SL, Hougham AJ. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol. 1998;38: Jablonska S. Traditional therapies for the treatment of condylomata acuminate (genital warts). Australas J Dermatol. 1998;39:S2-S Tran H, Chen K, Shumack S. Summary of actinic keratosis studies with imiquimod 5% cream. Br J Dermatol. 2003;149: Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol. 2002;47: Savage P, Horton V, Moore J, Owens M, Witt P, Gore ME. A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. Br J Cancer. 1996; 74: Owen ML, Bridson WE, Smith SL, Myers JA, Fox TL, Wells TM. Percutaneous penetration of Aldara TM cream, 5% during the topical treatment of genital and perianal warts. Prim Care Update Ob Gyns. 1998;5:
Treatment of Bowenoid and Basaloid Vulvar Intraepithelial Neoplasia 2/3 with Imiquimod 5% Cream DO NOT DUPLICATE
The Journal of Reproductive Medicine Treatment of Bowenoid and Basaloid Vulvar Intraepithelial Neoplasia 2/3 with Imiquimod 5% Cream Claudia Marchitelli, M.D., Graciela Secco, M.D., Myriam Perrotta, M.D.,
More informationTreatment for Vulvar Intraepithelial Neoplasia II/III Bowenoid or Basaloid with Imiquimod 5% cream.
Treatment for Vulvar Intraepithelial Neoplasia II/III Bowenoid or Basaloid with Imiquimod 5% cream. Authors: Marchitelli C; Secco G; Perrotta M; Lugones L; Pesce R; Testa R Claudia Marchitelli: Vulvar
More informationDiseases of the vulva
Diseases of the vulva 1. Bartholin Cyst - Infection of the Bartholin gland produces an acute inflammation within the gland (adenitis) and may result in an abscess. Bartholin duct cysts - Are relatively
More informationDisorders of the vulva
Vulval lesions Disorders of the vulva Terminology standardised by the International Society for the Study of Vulvovaginal Disease(ISSVD) Classification 1.Nonneoplastic epithelial disorders of vulva Lichen
More informationVIN/VAIN O C T O B E R 3 RD J M O R G A N
VIN/VAIN O C T O B E R 3 RD 2 0 1 8 J M O R G A N Vaginal Intraepithelial Neoplasia VAIN I, II, III Incidence 0.1/100,000 women in US Mean age 50s (J Womens Health (Larchmt) 2009:18:1731) (J Obstet Gynaecol
More informationEfficacy of 5% Imiquimod Cream on Vulvar Intraepithelial Neoplasia in Korea: Pilot Study
JM Kim, et al Ann Dermatol Vol. 7, No. 1, 1 http://dx.doi.org/.1/ad.1.7.1.66 ORIGINAL ARTICLE Efficacy of % Imiquimod Cream on Vulvar Intraepithelial Neoplasia in Korea: Pilot Study Jeong-Min Kim 1, Hyun-Joo
More informationClinical Scoring System to Detect Malignant and Premalignant Vulval Lesions
The Journal of Obstetrics and Gynecology of India (January February 2014) 64(1):41 46 DOI 10.1007/s13224-013-0458-3 ORIGINAL ARTICLE Clinical Scoring System to Detect Malignant and Premalignant Vulval
More informationHPV-related papillomatous-condylomatous lesions in female anogenital area
HPV-related papillomatous-condylomatous lesions in female anogenital area Theo Panoskaltsis MD, FRCOG, CCST (UK) Epidemiology Anal cancer is increasing in both men and women Groups at risk: - HIV (+)
More informationClinically Microscopically Pathogenesis: autoimmune not lifetime
Vulvar Diseases: Can be divided to non-neoplastic and neoplastic diseases. The neoplastic diseases are much less common. Of those, squamous cell carcinoma is the most common. most common in postmenopausal
More informationVULVAR CARCINOMA. Page 1 of 5
VULVAR CARCINOMA EXAMPLE OF A VULVAR CARCINOMA USING PROPOSED TEMPLATE Case: Invasive squamous cell carcinoma arising in D-VIN Tumor in left labia major Left partial vaginectomy and sentinel lymph node
More informationPrevalence Of Precancerous Lesions Of The Uterine Cervix
Prevalence Of Precancerous Lesions Of The Uterine Cervix 1 / 6 2 / 6 3 / 6 Prevalence Of Precancerous Lesions Of INTRODUCTION. Gastric intestinal metaplasia is an intermediate precancerous gastric lesion
More informationVaginal intraepithelial neoplasia
Vaginal intraepithelial neoplasia The terminology and pathology of VAIN are analogous to those of CIN (VAIN I-III). The main difference is that vaginal epithelium does not normally have crypts, so the
More informationGenital Human Papillomavirus (HPV) Infections
Genital Human Papillomavirus (HPV) Infections January 2008 Etiology... 1 Epidemiology... 1 Prevention... 2 Diagnosis... 3 Management... 6 Treatment... 7 Consideration for Other STIs... 9 Reporting and
More informationAppropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines
Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Tim Kremer, MD Ralph Anderson, MD 1 Objectives Describe the natural history of HPV particularly as it relates
More informationAldara. Aldara (imiquimod) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.19 Subject: Aldara Page: 1 of 5 Last Review Date: March 17, 2017 Aldara Description Aldara (imiquimod)
More informationJean Anderson, MD Catherine Sewell, MD, MPH
Jean Anderson, MD Catherine Sewell, MD, MPH To review diagnosis and management of HPV disease in the setting of HIV infection and address controversies HIV-infected women have: higher prevalence and incidence
More informationMohs surgery for the nail unit
Mohs surgery for the nail unit olivier.cogrel@chu-bordeaux.fr Dermatologic surgery, Mohs surgery and lasers unit CHU Bordeaux, France Squamous cell carcinoma +++ Acral lentiginous melanoma Lichte et al.
More informationHuman Papillomavirus Induced Squamous Intraepithelial Lesions in Vulvar Lichen Planus
ORIGINAL RESEARCH ARTICLE Human Papillomavirus Induced Squamous Intraepithelial Lesions in Vulvar Lichen Planus Sigrid Regauer, MD, 1 Barbara Eberz, MD, 2 and Olaf Reich, MD 3 Objectives: Approximately
More informationONCOGENIC BALANITIS. G. Tchernev 1, J. Ananiev 2, J. C. Cardoso 3, S. Philipov 4 and U. Wollina 5
ONCOGENIC BALANITIS G. Tchernev 1, J. Ananiev 2, J. C. Cardoso 3, S. Philipov 4 and U. Wollina 5 1 Polyclinic for Dermatology and Venerology, University Hospital Lozenetz, Saint Kliment Ohridski University,
More informationThe use of CO2 laser for patients with Lichen sclerosus
The use of CO2 laser for patients with Lichen sclerosus Dr. Christina Kuhler-Obbarius, Elisabeth Kunkel, Dr. Matthias Theden-Schow, Hamburg, Germany Our clinical center located in Hamburg includes eight
More informationA Randomized, Double-Blind, Placebo-Controlled Trial of 5-Fluorouracil for the Treatment of Cervicovaginal Human Papillomavirus
Infectious Diseases in Obstetrics and Gynecology 7:186-189 (1999) (C) 1999 Wiley-Liss, Inc. A Randomized, Double-Blind, Placebo-Controlled Trial of 5-Fluorouracil for the Treatment of Cervicovaginal Human
More informationHPV and Genital Dermatology. Jean Anderson MD Director, Johns Hopkins HIV Women s Health Program June 2017
HPV and Genital Dermatology Jean Anderson MD Director, Johns Hopkins HIV Women s Health Program June 2017 Gilead-own stock Disclosures Objectives Describe epidemiology of genital HPV infection in the US
More informationInformation leaflet on. Vulval Intraepithelial Neoplasia VIN
Information leaflet on Vulval Intraepithelial Neoplasia VIN What is wrong with me? You have been found to suffer from Vulval Intraepithelial Neoplasia or VIN. This is an uncommon skin condition, which
More informationVulvar squamous cell carcinoma
The Clinical Significance of Stratifying Vulval Squamous Carcinoma into HPV and Non-HPV Related Variants C. BLAKE GILKS MD FRCPC Dept of Pathology, University of British Columbia Vulvar squamous cell carcinoma
More informationEpidemiology, diagnosis and treatment of vulvar intraepithelial neoplasia Elmar A. Joura
Epidemiology, diagnosis and treatment of vulvar intraepithelial neoplasia Elmar A. Joura The incidence of human papilloma virus-related vulvar intraepithelial neoplasia is increasing worldwide. This is
More informationVaginal involvement in genital erosive lichen planus
Acta Obstetricia et Gynecologica. 2010; 89: 966 970 SHORT REPORT Vaginal involvement in genital erosive lichen planus ANNE LISE ORDING HELGESEN 1,2,3, PETTER GJERSVIK 3,4, PETER JEBSEN 5, ROLF KIRSCHNER
More informationTreatment of Vulvar Intraepithelial Neoplasia with Topical Imiquimod
original article Treatment of Vulvar Intraepithelial Neoplasia with Topical Imiquimod Manon van Seters, M.D., Marc van Beurden, M.D., Ph.D., Fiebo J.W. ten Kate, M.D., Ph.D., Ilse Beckmann, M.Sc., Ph.D.,
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER VULVAR
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER VULVAR Last Revision Date July 2015 1 Site Group: Gynecologic Cancer Vulvar Author: Dr. Stephane Laframboise 1. INTRODUCTION
More informationUpdate of the role of Human Papillomavirus in Head and Neck Cancer
Update of the role of Human Papillomavirus in Head and Neck Cancer 2013 International & 12 th National Head and Neck Tumour Conference Shanghai, 11 13 Oct 2013 Prof. Paul KS Chan Department of Microbiology
More informationSummary. Accepted for publication 18 May Key words genital lichen planus, oral lichen planus, vulval lichen planus
CLINICAL AND LABORATORY INVESTIGATIONS DOI 10.1111/j.1365-2133.2006.07480.x Prevalence of vulval lichen planus in a cohort of women with oral lichen planus: an interdisciplinary study P. Belfiore, O. Di
More informationMEDICAL POLICY SUBJECT: HIGH RESOLUTION ANOSCOPY
MEDICAL POLICY SUBJECT: HIGH RESOLUTION ANOSCOPY PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including
More informationVulvar intraepithelial neoplasia: Current concepts
Vulvar intraepithelial neoplasia: Current concepts L. Stewart Massad, M.D. Dept. of Obstetrics & Gynecology Washington University School of Medicine St. Louis, MO Disclosure I have no financial ties to
More informationThe incidence of vulvar intraepithelial neoplasia
Loop Electrosurgical Excision Procedure in Vulvar Intraepithelial Neoplasia Treatment Anne-Thérèse Vlastos, MD, 1 Larry B. Levy, PhD, 2 Anais Malpica, MD, 3 and Michele Follen, MD, PhD 4 1 Département
More informationMeet the ISSVD. President ISSVD. Jacob Bornstein, MD
Meet the ISSVD Jacob Bornstein, MD President ISSVD Chairman, Department of Obstetrics and Gynecology Western Galilee Hospital Bar-Ilan University Faculty of Medicine Nahariya, Israel ISSVD Symposium: The
More informationHuman Papilloma Viruses HPV Testing and Treatment of STDs
Human Papilloma Viruses HPV Testing and Treatment of STDs New York State Collaborative Efforts in Medical Evaluations of Child and Adolescent Sexual Offenses. Child and Adolescent Sexual Offense Post-Assault
More informationFaculty Pap Smear Guidelines: Family Planning Update 2008 Part Two
Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two Seshu P. Sarma, MD, FAAP Emory University Regional Training Center Atlanta, Georgia Produced by the Alabama Department of Public Health
More informationHCT Medical Policy. High-Resolution Anoscopy for Evaluation of Anal Lesions Policy # HCT109 Current Effective Date: 10/30/2014.
HCT Medical Policy High-Resolution Anoscopy for Evaluation of Anal Lesions Policy # HCT109 Current Effective Date: 10/30/2014 Medical Policies are developed by HealthyCT to assist in administering plan
More informationVulval Intraepithelial Neoplasia (VIN)
Vulval Intraepithelial Neoplasia (VIN) Exceptional healthcare, personally delivered What is it? Vulval intraepithelial neoplasia (VIN) is a condition where there are pre-cancerous cells in the skin of
More informationHuman Papillomavirus (HPV) in Patients with HIV.
Human Papillomavirus (HPV) in Patients with HIV www.hivguidelines.org Purpose of the Guideline Increase the numbers of NYS residents with HIV who are screened for HPV-related dysplasia and managed effectively.
More informationLearning Objectives. What is HPV? Incidence in the U.S. 5/22/2013. Human papillomavirus Infections
Human papillomavirus Infections Anne Rompalo, MD, ScM Professor of Medicine Learning Objectives By the end of the presentation the participants will be able to: Describe the role of persistent HPV infection
More informationTopical Diclofenac Gel, Fluorouracil Cream, Imiquimod Cream, and Ingenol Gel Prior Authorization with Quantity Limit Program Summary
Topical Diclofenac Gel, Fluorouracil Cream, Imiquimod Cream, and Ingenol Gel Prior Authorization with Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1-8 Topical Diclofenac Gel Indication
More informationHuman Papillomavirus. Kathryn Thiessen, ARNP, ACRN The Kansas AIDS Education and Training Center The University of Kansas School of Medicine Wichita
Human Papillomavirus Kathryn Thiessen, ARNP, ACRN The Kansas AIDS Education and Training Center The University of Kansas School of Medicine Wichita What is Genital HPV Infection Human papillomavirus is
More informationEXTERNAL ANOGENITAL WARTS
EXTERNAL ANOGENITAL WARTS Whats new HPV vaccination is now available to MSM under the age of 45 years attending Sexual Health Services. This vaccination is recommended even if a prior/current history of
More informationInformation about your HANS assessment, HPV and AIN
Information about your HANS assessment, HPV and AIN Incorporating hospital and community health services, teaching and research This booklet has been written for people attending the Homerton anal neoplasia
More informationFORUM 044 VULVAR DISEASE: WHAT DO YOU KNOW? AN OVERVIEW
FORUM 044 VULVAR DISEASE: WHAT DO YOU KNOW? AN OVERVIEW Vulvar Neoplasms: Benign and Malignant Jill Allbritton, MD March 2, 2019 NO DISCLOSURES WITH INDUSTRY Jill Allbritton, MD Forum 044 Vulvar Disease:
More information3/25/2019. J. Anthony Rakowski D.O., F.A.C.O.O.G. MSU SCS Board Review Coarse
J. Anthony Rakowski D.O., F.A.C.O.O.G. MSU SCS Board Review Coarse 1 4 th most common GYN cancer 5% of malignancies of GYN type. 4850 new cases annually 1030 deaths Cigarette smoking Vulvar dystrophy (Lichen
More informationMEDICAL POLICY EFFECTIVE DATE: 12/20/12 REVISED DATE: 11/21/13, 10/16/14 SUBJECT: HIGH RESOLUTION ANOSCOPY
MEDICAL POLICY PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationArticles. Funding Cancer Research UK. Copyright Tristram et al. Open Access article distributed under the terms of CC BY.
Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT³VIN): a multicentre, open-label, randomised, phase 2 trial Amanda Tristram*, Christopher
More informationBottoms UP HIV and Anal Cancer from Screening to Prevention
Bottoms UP HIV and Anal Cancer from Screening to Prevention Paul MacPherson PhD, MD, FRCPC Associate Professor Division of Infectious Diseases University of Ottawa The New Reality Normal or near-normal
More informationLarge majority caused by sun exposure Often sun exposure before age 20 Persons who burn easily and tan poorly are at greatest risk.
Basics of Skin Cancer Detection and Treatment of Non- Melanoma Skin Cancers Large majority caused by sun exposure Often sun exposure before age 20 Persons who burn easily and tan poorly are at greatest
More informationVulval intraepithelial neoplasia: clinical review
Genitourin Med 1987;63:147-152 Review article Vulval intraepithelial neoplasia: clinical review Nomenclature Preinvasive neoplasia ofthe vulva has been recognised for over 75 years, but terminology to
More informationWoo Dae Kang, Ho Sun Choi, Seok Mo Kim
Is vaccination with quadrivalent HPV vaccine after Loop Electrosurgical Excision Procedure effective in preventing recurrence in patients with High-grade Cervical Intraepithelial Neoplasia (CIN2-3)? Chonnam
More informationShould Anal Pap Smears Be a Standard of Care in HIV Management?
Should Anal Pap Smears Be a Standard of Care in HIV Management? Gordon Dickinson, M.D., FACP Professor of Medicine and Chief Infectious Diseases, Miller School of Medicine Short Answer: NO But 15-20 HPV
More informationCLINICAL SCIENCE. doi: /S
CLINICS 2009;64(10):961-6 CLINICAL SCIENCE TREATMENT OF CUTANEOUS TUMORS WITH TOPICAL 5% IMIQUIMOD CREAM Sabrina Sisto Alessi, Jose Antonio Sanches, Walmar Roncalli de Oliveira, Maria Cristina Messina,
More informationMEDICAL POLICY SUBJECT: HIGH RESOLUTION ANOSCOPY EFFECTIVE DATE: 12/20/12 REVISED DATE: 11/21/13, 10/16/14, 09/17/15, 9/15/16 ARCHIVED DATE: 09/21/17
MEDICAL POLICY SUBJECT: HIGH RESOLUTION ANOSCOPY PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationLichen sclerosus. Lichen planus
Lichen sclerosus Lichen planus Dr Fiona Lewis, Consultant Dermatologist, Heatherwood and Wexham Park NHS Foundation Trust & St John s Institute of Dermatology, GSTT Outline Typical features of lichen sclerosus
More informationHuman Papillomavirus
Human Papillomavirus Dawn Palaszewski, MD Assistant Professor of Obstetrics and Gynecology University of February 18, 2018 9:40 am Dawn Palaszewski, MD Assistant Professor Department of Obstetrics and
More informationHPV and Lower Genital Tract Disease. Simon Herrington University of Edinburgh, UK Royal Infirmary of Edinburgh, UK
HPV and Lower Genital Tract Disease Simon Herrington University of Edinburgh, UK Royal Infirmary of Edinburgh, UK Conflict of interest/funding X None Company: Product royalties Paid consultant Research
More informationEradicating Mortality from Cervical Cancer
Eradicating Mortality from Cervical Cancer Michelle Berlin, MD, MPH Vice Chair, Obstetrics & Gynecology Associate Director, Center for Women s Health June 2, 2009 Overview Prevention Human Papilloma Virus
More informationAsymptomatic Undiagnosed Lichen Sclerosus
Asymptomatic Undiagnosed Lichen Sclerosus Lynette J. Margesson MD FRCPC Assistant Professor of Obstetrics & Gynecology and Surgery(Dermatology) Geisel School of Medicine at Dartmouth Lebanon, NH, USA Disclosures
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 26 November 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 26 November 2008 ALDARA 5%, cream Box of 12 sachets of 250 mg (CIP: 349 204-4) Applicant: MEDA PHARMA imiquimod ATC
More informationMaking Sense of Cervical Cancer Screening
Making Sense of Cervical Cancer Screening New Guidelines published November 2012 Tammie Koehler DO, FACOG The incidence of cervical cancer in the US has decreased more than 50% in the past 30 years because
More informationVulval intraepithelial neoplasia. Information for patients Gynaecology
Vulval intraepithelial neoplasia Information for patients Gynaecology page 2 of 8 What is vulval intraepithelial neoplasia? Vulval intraepithelial neoplasia (VIN) is not cancer. VIN is a disease of the
More informationPremalignant skin tumours
Chapter 14: Premalignant skin tumours page: 434 Premalignant skin tumours page: 435 Solar keratoses (senile keratoses) Raised red and well-defined plaques with a rough surface covered in scales of varying
More informationHIV-infected men and women. Joel Palefsky, M.D. University of California, San Francisco
Anal cytology and anal cancer in HIV-infected men and women. Joel Palefsky, M.D. University of California, San Francisco April 10, 2010 Disclosures Merck and Co: Research grant support, advisory boards
More informationDisclosures. I have no conflicts of interest to disclose. Vulvar Disease. Precancer and Cancerous Vulvar Disease
Precancer and Cancerous Vulvar Disease Stefanie M. Ueda, M.D. Disclosures I have no conflicts of interest to disclose. Assistant Clinical Professor Division of Gynecologic Oncology University of California,
More informationIJC International Journal of Cancer
IJC International Journal of Cancer Randomised trial on treatment of vaginal intraepithelial neoplasia Imiquimod, laser vaporisation and expectant Karoliina Tainio 1, Maija Jakobsson 1, Karolina Louvanto
More informationThe Case of Mrs. Virginia Jones* Asst. Professor Division of Gyne-Oncology University of British Columbia, Department of Gynecology Vancouver, Canada
Case title: Case authors: Case synopsis: The Case of Mrs. Virginia Jones* Dr. Leslie A. Sadownik Asst. Professor Division of Gyne-Oncology University of British Columbia, Department of Gynecology Vancouver,
More information04/09/2018. Squamous Cell Neoplasia and Precursor Lesions. Agenda. Squamous Dysplasia. Squamo-proliferative lesions. Architectural features
Squamous Cell Neoplasia and Precursor Lesions Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology Chair of Pathology and Laboratory Medicine University of Arkansas for Medical
More informationHOW TO DIAGNOSE VULVAR DISEASES:
HOW TO DIAGNOSE VULVAR DISEASES: Diagnostic approach. Normal findings. Maria Sol Peremateu, MD A wide spectrum of benign, premalignant, and malignant lesions may occur on the vulva. Some of the disorders
More informationPostmenopausal Vulvar Pruritus - Colposcopic Diagnosis and Treatment
Postmenopausal Vulvar Pruritus - Colposcopic Diagnosis and Treatment Pages with reference to book, From 315 To 317 A Bilge Sener, Neslihan C. Seckin, Oya Gokmen ( Departments of Menopause, Dr. Z.T.B. Women
More informationWOMEN S INTERAGENCY HIV STUDY LABORATORY - PELVIC EXAM STUDIES TREATMENT FORM FORM L16
WOMEN S INTERAGENCY HIV STUDY LABORATORY - PELVIC EXAM STUDIES TREATMENT FORM FORM L16 ID LABEL HERE ---> - - - VISIT #: FORM COMPLETED BY: VERSION DATE: 05/01/95 ANY MISSING OR INCOMPLETE TEST RESULTS
More informationTopical immunomodulation. Charoen Choonhakarn,MD Division of Dermatology Khon Kaen University
Topical immunomodulation Charoen Choonhakarn,MD Division of Dermatology Khon Kaen University Vitiligo Atopic dermatitis Seborrheic dermatitis Oral lichen planus Anogenital warts Bowen s disease actinic
More informationDiagnostic difficulties with lesions of the oral mucosa
BDIAP London, November 2010 School of Clinical Dentistry University of Sheffield Diagnostic difficulties with lesions of the oral mucosa Paul M Speight Dept Oral & Maxillofacial Pathology University of
More informationchapter 4. The effect of oncogenic HPV on transformation zone epithelium
chapter 4. The effect of oncogenic HPV on transformation zone epithelium CHAPTER 1 All squamous cervical cancer (and probably all cervical adenocarcinoma) is associated with oncogenic HPV, and the absence
More informationالطلاوة = Leukoplakia LEUKOPLAKIA
LEUKOPLAKIA Leukoplakia is a clinical term that refers to a predominantly white lesion of the oral mucosa that cannot be rubbed off or characterized by any other definable lesion or known disease. 130
More information1.Acute and Chronic Cervicitis - At the onset of menarche, the production of estrogens by the ovary stimulates maturation of the cervical and vaginal
Diseases of cervix I. Inflammations 1.Acute and Chronic Cervicitis - At the onset of menarche, the production of estrogens by the ovary stimulates maturation of the cervical and vaginal squamous mucosa
More informationOvarian function and pregnancy after Hematopoietic Stem Cell Transplant
Ovarian function and pregnancy after Hematopoietic Stem Cell Transplant Factors that influence post transplantation fertility and ovarian function in women Total body irradiation (TBI) Drugs prescribed
More informationCarcinomas escamosos de vulva y vagina. Relación con HPV
Carcinomas escamosos de vulva y vagina. Relación con HPV Dr. Jaume Ordi Servei d Anatomia Patològica Hospital Clínic. Barcelona jordi@clinic.ub.es - 1 - Carcinoma de cérvix y VPH International Biological
More informationEfficacy of cervical intrarepithelial neoplasia (CIN)
The Ulster Medical Journal, Volume 72, No. 1, pp. 10-15, May 2003. Efficacy of cervical intrarepithelial neoplasia (CIN) treatment by cold coagulation A Zawislak, J H Price, H R McClelland, R G N Storey,
More informationWhen Immunostains Can Get You in Trouble: Gynecologic Pathology p16: Panacea or Pandora s Box?
When Immunostains Can Get You in Trouble: Gynecologic Pathology p16: Panacea or Pandora s Box? Teri A. Longacre, MD Stanford Medicine Stanford California pi6 in Gynecologic Pathology: Panacea or Pandora
More information11/1/18. Age and Vulvar Pathology ANATOMY. Prepuce Clitoris Vestibule Hart line. Labia. minora. Labia. majora. Fourchette.
Age and Vulvar Pathology Maria Angelica Selim, MD Professor of Pathology and Dermatology Director Dermatopathology Unit Duke University Medical Center Labia minora Labia majora Bartholin s duct Prepuce
More informationFocus. International #52. HPV infection in High-risk HPV and cervical cancer. HPV: Clinical aspects. Natural history of HPV infection
HPV infection in 2014 Papillomaviruses (HPV) are non-cultivable viruses with circular DNA. They can establish productive infections in the skin (warts) and in mucous membranes (genitals, larynx, etc.).
More informationFor personal use only
For mass reproduction, content licensing and permissions contact Dowden Health Media. OBG M ANAGEMENT Philip J. DiSaia, MD Professor and Director Division of Gynecologic Oncology Dorothy Marsh Chair in
More informationReduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy
ACTA BIOMED 2007; 78: 36-40 Mattioli 1885 O R I G I N A L A R T I C L E Reduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy
More informationLABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L14
LABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L4 ID LABEL HERE ---> - - - VISIT #: FORM COMPLETED BY: VERSION DATE: 08/5/94 ANY MISSING OR INCOMPLETE TEST RESULTS MUST BE EXPLAINED ON THIS FORM.
More informationThe Management of Minor Degrees of Cervical Dysplasia Associated with the Human Papilloma Virus
THE YALE JOURNAL OF BIOLOGY AND MEDICINE 64 (1991), 591-597 The Management of Minor Degrees of Cervical Dysplasia Associated with the Human Papilloma Virus JOHN A. CARMICHAEL, M.D., C.M., F.R.C.S.C. Division
More informationSupplementary Table 1: Study and sample characteristics of the included studies
Supplementary Table 1: Study and sample characteristics of the included studies First author, Imiquimod 5% cream vs. placebo Arican et al. 2004 34 Beutner et al. 1998a 35 Tyring et al. 1998a 36 Beutner
More informationTime series analysis of TP53 gene mutations in recurrent HPV-negative vulvar squamous cell carcinoma
Time series analysis of TP53 gene mutations in recurrent HPV-negative vulvar squamous cell carcinoma Karl Kashofer, Phd Institut für Pathologie Medizinische Universität Graz Disclosures Member of Clinical
More informationLeukocyte Ultrafiltrate
Infectious Diseases in Obstetrics and Gynecology 8:120-123 (2000) (C) 2000 Wiley-Liss, Inc. Immunotherapy of Gynaecological High-Risk Human Papilloma Virus Infection With Human Leukocyte Ultrafiltrate
More informationIt has been estimated that 90% of individuals
Famciclovir for Cutaneous Herpesvirus Infections: An Update and Review of New Single-Day Dosing Indications Manju Chacko, MD; Jeffrey M. Weinberg, MD Infections with herpes simplex virus (HSV) types 1
More informationSkin lesions The Good and the Bad. Dr Virginia Hubbard Ipswich Hospital NHS Trust Barts and the London School of Medicine and Dentistry
Skin lesions The Good and the Bad Dr Virginia Hubbard Ipswich Hospital NHS Trust Barts and the London School of Medicine and Dentistry Case 1 32 year old woman Australian Lesion on back New hair growing
More informationImiquimod Cream: A New Multipurpose Topical Therapy for Dermatology
Imiquimod Cream: A New Multipurpose Topical Therapy for Dermatology David J. Najarian, BS, and Joseph C. English III, MD Educational Objectives Review the literature on the reported uses of imiquimod in
More informationYearly pelvic exam, or not?
Yearly pelvic exam, or not? Are the new cancer screening guidelines putting patients at risk? Dianna Wachtel, DHSc, PA-C, CCPA CAPA 2018 Learning Objectives Distinguish between current PAP test guidelines
More informationYour Diagnosis Is? Test Your Knowledge of Various Vulvovaginal Conditions
Your Diagnosis Is? Test Your Knowledge of Various Vulvovaginal Conditions Hope K. Haefner, MD Professor University of Michigan Health System Ann Arbor, Michigan February, 2017 Industry Support and Financial
More informationHPV Infection and associated disease among HIV positive individuals. Admire Chikandiwa. Wits RHI
HPV Infection and associated disease among HIV positive individuals Admire Chikandiwa Wits RHI Outline of presentation Introduction Burden of HPV associated diseases The role of HIV and its interaction
More informationcamellia sinensis (green tea) leaf extract 10% ointment (Catephen ) SMC No. (1133/16) Kora Healthcare
camellia sinensis (green tea) leaf extract 10% ointment (Catephen ) SMC No. (1133/16) Kora Healthcare 04 March 2016 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationDepartment of Pathology, Kathmandu Medical College & Teaching Hospital, Sinamangal, Kathmandu, Nepal
Kathmandu University Medical Journal (2007), Vol. 5, No. 4, Issue 20, 461-467 Original Article Correlation of PAP smear findings with clinical findings and cervical biopsy Pradhan B 1, Pradhan SB 2, Mital
More informationCervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013
Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines General Principles: Since its introduction in 1943, Papanicolaou (Pap) smear is widely
More informationHuman Papillomavirus Infection
National STD Curriculum PDF created September 25, 2018, 6:35 pm Human Papillomavirus Infection This is a PDF version of the following document: Disease Type 1: Pathogen-Based Diseases Disease 11: Human
More information